Loading...
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.
Lawlor, Brian; Kennelly, Sean; O'Dwyer, Sarah; Cregg, Fiona; Walsh, Cathal Dominic; Cohen, Robert; Kenny, Rose Anne; Howard, Robert; Murphy, Caroline; Adams, Jessica; Daly, Leslie; Segurado, Ricardo; Gaynor, Siobhan; Crawford, Fiona; Mullan, Michael; Lucca, Ugo; Banzi, Rita; Pasquier, Florence; Breuilh, Laetitia; Riepe, Matthias W.; Kalman, Janos; Wallin, Anders; Borjesson-Hanson, Anne; Molloy, William; Tsolaki, Magda; Rikkert, Marcel Olde
Date
2014
Abstract
This study is a European multicentre, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of nilvadipine as a disease course modifying treatment for mild-tomoderate Alzheimer’s disease (AD) in a phase III study that will run for a period of 82 weeks with a treatment period of 78 weeks
Supervisor
Description
peer-reviewed
Publisher
BMJ Publishing Group
Citation
BMJ Open;4: e006364
Collections
Files
Loading...
Walsh_2015_NILVAD.pdf
Adobe PDF, 1.04 MB
Keywords
ULRR Identifiers
Funding code
Funding Information
European Research Council (ERC)